CymaBay Therapeutics, Inc. Patent applications |
Patent application number | Title | Published |
20160075636 | Process for the Preparation of (-)-(4-Chloro-Phenyl)-(3-Trifluoromethyl-Phenoxy)-Acetic Acid 2-Acetylamino-Ethyl Ester - The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate. | 03-17-2016 |
20160051520 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof. | 02-25-2016 |
20150374649 | Treatment of Severe Hypertriglyceridemia - Treatment of severe hypertriglyceridemia, such as Type I or Type V hyperlipoproteinemia, by therapy with MBX-8025 or an MBX-8025 salt, alone or in combination with one or more of a fibrate, niacin, and an omega-3 fatty acid, optionally accompanied by apheresis. | 12-31-2015 |
20150290154 | Treatment of NAFLD and NASH - Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt. | 10-15-2015 |
20150265560 | Treatment of Intrahepatic Cholestatic Diseases - Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt. | 09-24-2015 |
20150258053 | Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and a Second Urate-Lowering Agent - Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof. | 09-17-2015 |
20150239881 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS - Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active. | 08-27-2015 |
20150197518 | SUBSTITUTED TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE SALTS - Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed. | 07-16-2015 |
20150139987 | TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - Treatment of homozygous familial hypercholesterolemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an MTP inhibitor, an apoB-100 synthesis inhibitor, or a PCSK9 inhibitor. | 05-21-2015 |